PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators
The degradation of overexpressed proteins has emerged as a promising strategy for halting disease progression, particularly in cancer. Traditional small-molecule drugs often face limitations in the elimination of pathogenic proteins, leading to the development of targeted protein degradation (TPD) a...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Taylor & Francis Group
2026-12-01
|
| Rangatū: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Ngā marau: | |
| Urunga tuihono: | https://www.tandfonline.com/doi/10.1080/14756366.2026.2636394 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|